Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease
Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence
Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused on late-stage Parkinson’s disease (PD), today announced a strategic global co-development agreement for Infudopa SubC® — a next-generation, wearable drug-device therapy that offers a user-friendly, flexible, and physiologically sound alternative to existing advanced Parkinson’s treatments, hence empowering patients with greater independence.
